Theranosticsin nuclear medicine and oncology
Nowadays, the incidence of tumors is constantly growing, affecting older patients who are frequently exhibiting comorbidities. The occurrence of side effects may represent a problem for treatment compliance of patients. In order to manage this challenge, improving patient selection, reducing adverse...
Main Authors: | Sergio Baldari, Benedetta Pagano, Salvatore Antonio Pignata |
---|---|
Format: | Article |
Language: | English |
Published: |
Accademia Peloritana dei Pericolanti
2019-04-01
|
Series: | Atti della Accademia Peloritana dei Pericolanti - Classe di Scienze Medico-Biologiche |
Subjects: | |
Online Access: | http://cab.unime.it/journals/index.php/APMB/article/view/2140 |
Similar Items
-
Recent Advancements, Challenges, and Future Prospects in Usage of Nanoformulation as Theranostics in Inflammatory Diseases
by: Amit K. Goyal, et al.
Published: (2023-03-01) -
Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer
by: Wietske I. Luining, et al.
Published: (2022-02-01) -
FAPi-Based Agents in Thyroid Cancer: A New Step towards Diagnosis and Therapy? A Systematic Review of the Literature
by: Priscilla Guglielmo, et al.
Published: (2024-02-01) -
Editorial: A year in review: discussions in nuclear medicine
by: Domenico Albano, et al.
Published: (2024-02-01) -
Editorial: Nuclear Medicine in the Context of Personalized Medicine
by: Jacques Barbet, et al.
Published: (2020-06-01)